JNJ TECVAYLI ups survival in Phase 3 multiple myeloma trial, FDA and EMA filings for earlier-line use

 

Johnson & Johnson's TECVAYLI improves survival in Phase 3 MajesTEC-9 multiple myeloma trial, with FDA and EMA filings for earlier-line use

• MajesTEC-9 showed TECVAYLI significantly improves progression-free and overall survival versus standard of care in earlier-line disease.
• Johnson & Johnson submitted applications to expand TECVAYLI use as early as second-line therapy in multiple myeloma.
• FDA approved an expanded TREMFYA label adding structural joint damage data for active psoriatic arthritis.

https://finviz.com/stock?t=JNJ&p=d